From cell cycle to clinical benefit: How is Dalpiciclib reshaping the landscape of HR+ breast cancer treatment?
Dalpiciclib inhibits tumor cell proliferation by suppressing CDK4/6 kinase activity and blocking phosphorylation of retinoblastoma proteins, thereby inducing G1 phase arrest.
